Zepbound, Ozempic, Wegovy and Mounjaro Stomach Pain, Bloating and Gas: How Common It Is and When It Is Serious
How often Zepbound, Wegovy, Ozempic and Mounjaro cause stomach pain, bloating and gas (farting) in trials, why it happens, red-flag pain and user stories.
Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →
Short answer
Stomach pain is one of the most common side effects of GLP-1 drugs. In the US prescribing information, abdominal pain was reported by 20% of people on Wegovy injection vs 10% on placebo, and by 9 to 10% on Zepbound vs 5% on placebo. Bloating (abdominal distension), gas and indigestion are also more common than on placebo. Most of it is mild, shows up while the dose is being increased, and fades. Severe or constant pain is different: it can be a sign of pancreatitis, gallbladder disease or a blocked bowel and needs urgent care. Not medical advice. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance. Facts checked October 29, 2026.
How common it is in the trials
From the adverse-reaction tables in the US labels for Wegovy, Zepbound, Ozempic and Mounjaro. Ranges cover the different maintenance doses; drug vs placebo. Wegovy and Zepbound were tested in weight-loss trials, Ozempic and Mounjaro in type 2 diabetes trials, so the numbers are not directly comparable.
| Drug | Stomach (abdominal) pain | Bloating (distension) | Gas (flatulence) | Indigestion (dyspepsia) |
|---|---|---|---|---|
| Wegovy (semaglutide) | 20% vs 10% | 7% vs 5% | 6% vs 4% | 9% vs 3% |
| Zepbound (tirzepatide) | 9–10% vs 5% | 3–4% vs 2% | 3–4% vs 2% | 9–10% vs 4% |
| Ozempic (semaglutide) | 5.7–7.3% vs 4.6% | Not in the label table | 0.4–1.5% vs 0.8% | 2.7–3.5% vs 1.9% |
| Mounjaro (tirzepatide) | 5–6% vs 4% | 0.4–2.9% vs 0.4% | 1.3–2.9% vs 0% | 5–8% vs 3% |
Gas and farting on GLP-1 drugs
Gas (flatulence in label language) is listed on all four labels but is less common than nausea or diarrhea. The Canadian monographs give similar figures to the US table above: Zepbound 3.2% to 4.0% vs 1.6% on placebo in the weight-management trials, Mounjaro 1.3% to 2.9% vs none on placebo in the diabetes trials, and Ozempic 0.5% to 1.5% vs 0.5% on comparators. Bloating and burping usually come with it.
Why it happens: these drugs slow digestion, so food spends longer in the gut where bacteria ferment it, which makes more gas. Sulfur-containing gases are what make it smell; the same process causes sulfur burps. Constipation, also common on GLP-1s, can trap gas and add to cramping (see GLP-1 constipation). Users often name large, fatty or very high-protein meals, fizzy drinks and sugar alcohols as triggers. Gas is usually worst in the first weeks and after dose increases. Not being able to pass any gas or stool, with a swollen belly or vomiting, is a red flag (see below).
Why GLP-1 drugs cause stomach pain and bloating
Semaglutide and tirzepatide slow how fast the stomach empties. Food sits longer, which helps people feel full but can also cause a heavy, stretched or crampy feeling, trapped gas and burping (see sulfur burps). Constipation is common on these drugs and is a frequent cause of lower belly pain and bloating (see GLP-1 constipation). Upper-belly burning is often reflux or indigestion (see GLP-1 heartburn). The Wegovy label notes that its gastrointestinal side effects were reported most often while the dose was being stepped up, and in the trials 4.3% of adults on Wegovy stopped because of a gastrointestinal side effect vs 0.7% on placebo. Many users describe large or fatty meals as a trigger. If pain is mild, a prescriber can help sort out whether it is constipation, reflux or something else.
Red flags: stomach pain that needs urgent care
The US labels carry warnings or post-marketing reports for most of these problems. Get same-day medical care for:
| What you notice | What it can be | More |
|---|---|---|
| Severe, constant pain in the upper belly, sometimes spreading to the back, with or without vomiting | Acute pancreatitis | GLP-1 pancreatitis |
| Pain in the upper right belly, fever, yellow skin or eyes, pale stools | Gallstones or gallbladder inflammation | GLP-1 gallbladder problems |
| Swollen, hard belly, cannot pass gas or stool, repeated vomiting | Ileus or bowel obstruction (reported after approval) | GLP-1 constipation |
| Fullness for hours, vomiting food eaten long before | Severely delayed stomach emptying | GLP-1 gastroparesis |
| Vomiting or diarrhea so bad you cannot keep fluids down | Dehydration, which can harm the kidneys | GLP-1 diarrhea |
Zepbound vs Ozempic vs Wegovy
There is no head-to-head trial on stomach pain alone. In the weight-loss trials, more people reported abdominal pain on Wegovy (20%) than on Zepbound (9 to 10%), but the trials, placebo rates and ways of counting differed, so this is not proof one is gentler. Ozempic and Mounjaro, used at diabetes doses, show lower rates in their own trials. People who switch drugs often report different side effects; that is individual, not predictable from the tables.
In Canada
The Canadian Ozempic monograph lists abdominal pain in 8.1 to 8.7% of people on Ozempic vs 4.7% on placebo in its diabetes trials, and the Canadian Wegovy monograph lists 20% vs 10% and tells prescribers to watch for persistent severe abdominal pain that may spread to the back as a sign of pancreatitis. More: Ozempic side effects in Canada and Mounjaro side effects in Canada.
What users report here
Stomach stories in live confessions (checked October 29, 2026) go both ways. #190 says the first month on tirzepatide their stomach "declared war", with rotten-egg burps, and that it calmed down around week 6. Two retatrutide users, a drug that is not approved anywhere, describe the opposite: #342 says long-running gas and bloating went away and came back during a week off, #760 jokes about "farting myself awake" in the first week, and #803 says period bloating and cramps eased. Stories, not rates.
Related topics
related peptides:
in Canada:
community guides:
More confessions from the archive
Community Q&A
- Does Zepbound cause stomach pain?
- Yes, for some people. In the US Zepbound label, 9 to 10% of people reported abdominal pain vs 5% on placebo, and 9 to 10% reported indigestion vs 4%.
- Does Ozempic cause bloating?
- Bloating is not in the main Ozempic table, but gas, indigestion and burping are listed. In Wegovy's weight-loss trials (same drug, semaglutide), abdominal distension was reported by 7% vs 5% on placebo.
- Does Zepbound cause gas?
- Yes, for some people. In the Zepbound weight-loss trials, 3.2% to 4.0% reported gas (flatulence) vs 1.6% on placebo, and 3.4% to 4.0% reported bloating vs 2.2%.
- Does Ozempic make you fart more?
- It can. Gas is a listed side effect of Ozempic, though in its diabetes trials only 0.5% to 1.5% reported it vs 0.5% on comparators. Rates were higher on Wegovy (same drug, weight-loss trials): 6% vs 4%.
- Why is gas on a GLP-1 so smelly?
- Slower digestion gives gut bacteria more time to ferment food, and sulfur-containing gases cause the smell. It is the same reason people get sulfur burps on these drugs.
- Where is GLP-1 stomach pain usually felt?
- Users describe upper-belly fullness or burning and lower-belly cramps from gas or constipation. Severe constant upper-belly pain spreading to the back, or pain on the upper right with fever or yellowing, needs urgent care.
- Does stomach pain on Ozempic or Zepbound go away?
- The labels say gastrointestinal side effects were most common while the dose was being increased, and many users say it settles within weeks. Pain that persists or gets worse should be checked.
- When is stomach pain on a GLP-1 an emergency?
- Severe or constant pain, pain with repeated vomiting, a swollen hard belly with no gas or stool, or pain with fever or yellow skin. These can be pancreatitis, gallbladder disease or a blocked bowel.
- Does this page give dosing advice?
- Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.
Sources
Last reviewed November 11, 2026. Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.